The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression

Abstract

Genes of the polycomb group function by silencing homeotic selector genes that regulate embryogenesis. In mice, downregulation of one of the polycomb genes, bmi-1, leads to neurological alterations and severe proliferative defects in lymphoid cells, whilst bmi-1 overexpression, together with upregulation of myc-1, induces lymphoma. An oncogenic function has been further supported in primary fibroblast studies where bmi-1 overexpression induces immortalization due to repression of p16/p19ARF, and where together with H-ras, it readily transforms MEFs. It was the aim of this study to assess the expression of bmi-1 in resectable non-small cell lung cancer (NSCLC) in association with p16 and p14ARF (=human p19ARF). Tumours (48 resectable NSCLC (32 squamous, 9 adeno-, 2 large cell, 4 undifferentiated carcinomas and 1 carcinoid); stage I, 29, II, 7, III, 12; T1, 18, T2, 30; differentiation: G1 12, G2 19, G3 17) were studied by immunohistochemistry for protein expression and by comparative multiplex PCR for gene amplification analysis. In tumour-free, normal lung tissue from patients, weak - moderate bmi-1 staining was seen in some epithelial cells, lymphocytes, glandular cells and in fibroblasts, whereas blood, endothelial, chondrocytes, muscle cells and adipocytes did not exhibit any bmi-1 expression. In tumours, malignant cells were negative/weakly, moderately and strongly positive in 20, 22 and 6 cases, respectively. As assessed by multiplex PCR, bmi-1 gene amplification was not the reason for high-level bmi-1 expression. Tumours with moderate or strong bmi-1 expression were more likely to have low levels of p16 and p14ARF (P = 0.02). Similarly, tumours negative for both, p16 and p14ARF, exhibit moderate-strong bmi-1 staining. 58% of resectable NSCLC exhibit moderate-high levels of bmi-1 protein. The inverse correlation of bmi-1 and the INK4 locus proteins expression (p16/p14ARF) supports a possible role for bmi-1 misregulation in lung carcinogenesis.

References 22

1. 1.

   Alkema M. J., Bronk M., Verhoeven E., Otte A., van 't Veer L. J., Berns A., van Lohuizen M. Identification of Bmi1-interacting proteins as constituents of a multimeric mammalian polycomb complex. Genes Dev. 1997;11(2):226-240.

   Not in our library10.1101/gad.11.2.226

2. 2.

   Alkema M. J., Jacobs H., van Lohuizen M., Berns A. Pertubation of B and T cell development and predisposition to lymphomagenesis in Emu Bmi1 transgenic mice require the Bmi1 RING finger. Oncogene. 1997;15(8):899-910.

   Not in our library10.1038/sj.onc.1201262

3. 3.

   Alkema M. J., Wiegant J., Raap A. K., Berns A., van Lohuizen M. Characterization and chromosomal localization of the human proto-oncogene BMI-1. Hum Mol Genet. 1993;2(10):1597-1603.

   Not in our library10.1093/hmg/2.10.1597

4. 4.
   Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer · 1996

   No notice
5. 5.

   Betticher D. C., White G. R., Vonlanthen S., Liu X., Kappeler A., Altermatt H. J., Thatcher N., Heighway J. G1 control gene status is frequently altered in resectable non-small cell lung cancer. Int J Cancer. 1997;74(5):556-562.

   Not in our library10.1002/(sici)1097-0215(19971021)74:5<556::aid-ijc14>3.0.co;2-4

6. 6.

   Beà S., Ribas M., Hernández J. M., Bosch F., Pinyol M., Hernández L., García J. L., Flores T., González M., López-Guillermo A. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood. 1999;93(12):4365-4374.

   Not in our library

7. 7.

   Brunk B. P., Martin E. C., Adler P. N. Drosophila genes Posterior Sex Combs and Suppressor two of zeste encode proteins with homology to the murine bmi-1 oncogene. Nature. 1991;353(6342):351-353.

   Not in our library10.1038/353351a0

8. 8.

   Gould A. Functions of mammalian Polycomb group and trithorax group related genes. Curr Opin Genet Dev. 1997;7(4):488-494.

   Not in our library10.1016/s0959-437x(97)80075-5

9. 9.

   Haupt Y., Alexander W. S., Barri G., Klinken S. P., Adams J. M. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell. 1991;65(5):753-763.

   Not in our library10.1016/0092-8674(91)90383-a

10. 10.

    Jacobs J. J., Kieboom K., Marino S., DePinho R. A., van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature. 1999;397(6715):164-168.

    Not in our library10.1038/16476

11. 11.

    Lessard J., Baban S., Sauvageau G. Stage-specific expression of polycomb group genes in human bone marrow cells. Blood. 1998;91(4):1216-1224.

    Not in our library

12. 12.

    Paro R. Propagating memory of transcriptional states. Trends Genet. 1995;11(8):295-297.

    Not in our library10.1016/s0168-9525(00)89081-2

13. 13.

    Pomerantz J., Schreiber-Agus N., Liégeois N. J., Silverman A., Alland L., Chin L., Potes J., Chen K., Orlow I., Lee H. W. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell. 1998;92(6):713-723.

    Not in our library10.1016/s0092-8674(00)81400-2

14. 14.

    Voncken J. W., Schweizer D., Aagaard L., Sattler L., Jantsch M. F., van Lohuizen M. Chromatin-association of the Polycomb group protein BMI1 is cell cycle-regulated and correlates with its phosphorylation status. J Cell Sci. 1999;112(Pt 24):4627-4639.

    Not in our library10.1242/jcs.112.24.4627

15. 15.

    Vonlanthen S., Heighway J., Tschan M. P., Borner M. M., Altermatt H. J., Kappeler A., Tobler A., Fey M. F., Thatcher N., Yarbrough W. G. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. Oncogene. 1998;17(21):2779-2785.

    Not in our library10.1038/sj.onc.1202501

16. 16.

    Weber J. D., Taylor L. J., Roussel M. F., Sherr C. J., Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol. 1999;1(1):20-26.

    Not in our library10.1038/8991

17. 17.

    Whyte P. The retinoblastoma protein and its relatives. Semin Cancer Biol. 1995;6(2):83-90.

    Not in our library10.1006/scbi.1995.0011

18. 18.

    Zhang Y., Xiong Y., Yarbrough W. G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 1998;92(6):725-734.

    Not in our library10.1016/s0092-8674(00)81401-4

19. 19.

    van Lohuizen M., Frasch M., Wientjens E., Berns A. Sequence similarity between the mammalian bmi-1 proto-oncogene and the Drosophila regulatory genes Psc and Su(z)2. Nature. 1991;353(6342):353-355.

    Not in our library10.1038/353353a0

20. 20.

    van Lohuizen M. Functional analysis of mouse Polycomb group genes. Cell Mol Life Sci. 1998;54(1):71-79.

    Not in our library10.1007/s000180050126

21. 21.

    van Lohuizen M., Verbeek S., Scheijen B., Wientjens E., van der Gulden H., Berns A. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell. 1991;65(5):737-752.

    Not in our library10.1016/0092-8674(91)90382-9

22. 22.

    van der Lugt N. M., Domen J., Linders K., van Roon M., Robanus-Maandag E., te Riele H., van der Valk M., Deschamps J., Sofroniew M., van Lohuizen M. Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev. 1994;8(7):757-769.

    Not in our library10.1101/gad.8.7.757

Cited by papers we hold 5

• Mechanisms of Polycomb group protein function in cancer · 2022
  No notice
• Epigenetic Reprogramming and Emerging Epigenetic Therapies in CML · 2019
  Not checked
• Targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy · 2015
  No notice
• MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1 · 2011
  No notice
• GSK3β Regulates Differentiation and Growth Arrest in Glioblastoma · 2009
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.